QCNW-Liverpool has recently completed a stability study on Panitumumab preparations, which was undertaken at the request of Clatterbridge Cancer Centre and supported by Amgen®. Amgen Ltd had no input on either the study design or results.
A copy of the report has been supplied to the NHS Pharmaceutical Research and Development Working Group for review, with the intention the report can be utilised by the wider NHS pharmacy community.
Published: 26/07/2021 Published by: Quality Control North West Liverpool
Return to News Page.